Ultime notizie per XCF Global Capital (NASDAQ:SAFX) Azioni

XCF Global Capital Inc is engaged in producing Sustainable Aviation Fuel (SAF), committed to reducing the global carbon footprint through expanding the market for clean-burning, sustainable biofuels. The company is developing and operating state-of-the-art clean fuel SAF production facilities engineered to the highest levels of compliance, reliability, and quality.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

ADIL

BDMD

BLNE

CBIO

GCTK

KTOS

MKDW

MLKN

ORIS

PRTG

RVPH

SAFX

ZVSA

Worthington sorprende con utili superiori alle attese: +15,7% in pre-market. Balzi anche per VOR, ADIL e ALT. Ecco i titoli top di oggi.

Azioni di Worthington Steel salgono di oltre il 15%; Ecco 20 azioni in movimento nel pre-market USA

XCF Global Capital Inc

Barclays analyst Nicholas Campanella initiates coverage on NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) with a Overweight rating and announces Price Target of $197.

News

Price Target

Initiation

Analyst Ratings

Barclays Initiates Coverage On NRG Energy with Overweight Rating, Announces Price Target of $197

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $3 price target.

Reiteration

CGTX

HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

<ul>
<li>Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO.</li>
<li>Hervé Hoppenot to retire after 11 years of leading Incyte through major expansion.</li>
<li>Julian Baker elected Chairman of the Board of Directors</li>
</ul>

Biotech

Health Care

Management

General

INCY

Incyte appoints Bill Meury as President, CEO And Board Member, Effective Immediately

<ul>
<li>Demonstrated target engagement and response prediction for ALTO-203 by theta/beta ratio, a commonly used EEG index of cortical arousal and attentional control&nbsp;</li>
<li>ALTO-203, a non-stimulant compound which demonstrated pro-cognitive and wake-promoting effects, has the potential to address sustained attention abnormalities in EEG biomarker characterized patients&nbsp;</li>
<li>Pharmacodynamic activity is aligned with the proposed mechanism of ALTO-203; improvements in attention and corresponding reductions in EEG theta/beta ratio, as well as response prediction biomarker replicate Phase 1 study findings&nbsp;</li>
</ul>

ANRO

Alto Neuroscience Identifies EEG Biomarker And Reports Pharmacodynamic Results From Phase 2 Trial Of ALTO-203 For Major Depressive Disorder

Invenergy, America's largest privately held developer, owner and operator of clean energy solutions, and Meta Platforms, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) today announced they have signed four additional clean energy agreements that represent an additional 791 megawatts (MW) of procured solar and wind energy. The agreements will provide near-term energy to support Meta's operations, data center growth, and clean energy&nbsp;goals.
&nbsp;
The&nbsp;agreements&nbsp;come&nbsp;after&nbsp;the&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4457827-1&amp;h=1523568139&amp;u=https%3A%2F%2Finvenergy.com%2Fnews%2Finvenergy-to-provide-over-760mw-in-renewable-energy-supporting-meta-s-energy-needs-in-line-with-its-clean-and-renewable-energy-goals&amp;a=2024%C2%A0announcement">2024&nbsp;announcement</a> of Meta's 1,000 MW of total procured energy from Invenergy. Together, these projects bring the companies' partnership to a total of 1,800 MW, including over 740 MW of new energy generation in Ohio. The electricity from these projects will be delivered to the local grid, while Meta will receive the clean energy credits associated with the new generation capacity coming online.

Invenergy and Meta Sign Clean Energy Deals for 791 MW to Support Data Centers and Sustainability Goals

Transom Capital Group, LLC ("Transom"), an operationally focused middle-market private equity firm, today announced that it has commenced a cash tender offer to acquire all outstanding shares of common stock of SigmaTron International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMA#NASDAQ">SGMA</a>) (the "Company" or "SigmaTron"), an electronic manufacturing services company, at a price of $3.02 per share in cash. The tender offer is being made in connection with the previously announced Agreement and Plan of Merger, dated May 20, 2025 (as amended or supplemented from time to time, the "Merger Agreement").
Transom Offer Unanimously Recommended by SigmaTron Board&nbsp;of Directors
The SigmaTron Board&nbsp;of Directors (the "SigmaTron Board") unanimously determined that the offer and the merger are advisable and in the best interest of SigmaTron and its stockholders and recommends the stockholders tender their shares to Transom. The SigmaTron Board, with the assistance of its management team and advisors, engaged in a comprehensive review of a range of financial and strategic alternatives and engaged with over thirty parties to determine interest in a transaction. The SigmaTron Board also reviewed a proposal submitted by a third party following the announcement of the Merger Agreement. The third party subsequently communicated to the Company that it was no longer pursuing a transaction and withdrew its proposal.
Cash Consideration Provides Immediate Liquidity and Certainty of Value
The SigmaTron Board took into account various factors, including, among other things, the potential risks related to SigmaTron's significant level of indebtedness and the terms of such indebtedness, in its determination, as described further in SigmaTron's Schedule 14D-9 (as defined below). The SigmaTron Board believed the certainty of value provided by the $3.02 cash offer and the timing in which the transaction could be consummated, among other things, was in the best interests of SigmaTron's stockholders.
Tender Offer Details
On June 26, 2025, Transom filed with the U.S. Securities and Exchange Commission ("SEC") a tender offer statement on Schedule TO, including an offer to purchase and letter of transmittal (the "Schedule TO"), which sets forth the terms of the tender offer. Additionally, SigmaTron filed with the SEC a solicitation/recommendation statement on Schedule 14D-9 (the "Schedule 14D-9") that includes the recommendation of the SigmaTron Board that SigmaTron stockholders accept the tender offer and tender their shares.
The tender offer is scheduled to expire at one minute after 11:59 p.m., Eastern Time, on July 24, 2025, unless extended in accordance with the terms of the tender offer and Merger Agreement. Consummation of the tender offer is subject to customary terms and conditions, including the tender of a number of shares of common stock of SigmaTron which represents at least a majority of the voting power of SigmaTron and the satisfaction of other customary closing conditions. Following the successful closing of the tender offer, Transom will acquire any shares of SigmaTron that are not tendered in the tender offer through a second-step merger for the same consideration as paid in the tender offer.

SGMA

Transom Capital Group Commences Cash Tender Offer To Acquire All Outstanding Common Shares Of SigmaTron At $3.02/Shr In Cash

As the One Big Beautiful Bill Act of 2025 proposes tax relief for individuals, it is also estimated to increase the federal deficit. However, this expert proposes an idea that could help cut trillions of dollars in deficit.
What Happened: Financial commentator Ross Gerber of Gerber Kawasaki has ignited discussion with an X post, proposing to let the &#8220;tax cuts&#8221; expire and restore full State and Local Tax (SALT) deductions to slash the U.S. federal deficit by trillions.
Gerber targets the <a href="https://www.benzinga.com/personal-finance/25/05/45485150/the-one-big-beautiful-bill-would-create-maga-savings-accounts-with-a-1000-gift-from-the-government-at-birth">One Big Beautiful Bill Act</a>, a House-passed bill extending tax cuts and raising the SALT cap to $40,000, which faces Senate hurdles.
The tax cut bill is projected to add $3 trillion to the national debt over a decade, according to the Committee for a Responsible Federal Budget, a cost Gerber's plan seeks to avoid by letting its provisions lapse.
Restoring full SALT deductions—beyond the bill&#8217;s $40,000 limit—could benefit high-tax states like California, where residents often exceed the current $10,000 caps. However, this hinges on new legislation, as the 2017 Tax Cuts and Jobs Act (TCJA) SALT cap remains unless Congress acts.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Let the tax cuts expire and full SALT comes back. That would cut the deficit by trillions. People in California would also save money on taxes.
&mdash; Ross Gerber (@GerberKawasaki) <a href="https://twitter.com/GerberKawasaki/status/1938152101323878461?ref_src=twsrc%5Etfw">June 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/46109917/billionaire-david-tepper-dumps-nvidia-slashes-magnificent-7-holdings-but-bets-big-on-these-2-ai-and-blockchain-plays">Billionaire David Tepper Dumps Nvidia, Slashes &#8216;Magnificent 7&#8217; Holdings — But Bets Big On These 2 AI And Blockchain Plays</a>
Why It Matters: The estimates released by the Congressional Budget Office for the distributional effects of the One Big Beautiful Bill Act highlighted that tax changes, including extending provisions of the 2017 tax act, would lead to an <a href="https://www.benzinga.com/markets/equities/25/05/45536595/big-beautiful-bill-will-explode-the-deficit-and-make-the-rich-richer-congressional-budget-office-estimates-4-income-fall-for-lowest-decile-of-americans-by-2033">increase in the federal deficit by $3.8 trillion</a>.
Meanwhile, the CBO document also underscores a $698 billion reduction in federal subsidies from changes to the Medicaid program and $267 billion less in federal spending for the Supplemental Nutrition Assistance Program (SNAP).
The document also stated, "Household resources would decrease by an amount equal to about 2 percent of income in the lowest decile (tenth) of the income distribution in 2027 and 4 percent in 2033, mainly as a result of losses of in-kind transfers, such as Medicaid and SNAP."
On the other hand, resources would increase by an amount equal to 4% for households in the highest decile in 2027 and 2% in 2033, mainly because of "reductions in the taxes they owe."
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Thursday. The SPY was up 0.34% at $609.18, while the QQQ advanced 0.46% to $543.64, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46068345/blackrock-bets-big-on-defense-companies-amid-escalating-geopolitical-tensions-palantir-lockheed-martin-northrop-grumman-among-stocks-in-focus" target="_blank" rel="noreferrer noopener">BlackRock Bets Big On Defense Companies Amid Escalating Geopolitical Tensions: Palantir, Lockheed Martin, Northrop Grumman Among Stocks In Focus</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. 
Image via Shutterstock

Ross Gerber Touts An Idea To Cut Deficit By Trillions Of Dollars: 'Let The Tax Cuts Expire And Full SALT Come Back'

ASTS

AST SpaceMobile and Fairwinds Demonstrate World's First Space-Based Tactical Broadband to Standard Smartphones With U.S. Defense Participation

PLMR

Palomar And Neptune Join Forces To Expand Flood Insurance Availability Using AI And Data Science For Streamlined Solutions

BBIO

BridgeBio Says It Will Host Investor Webinar On July 11 Featuring Matthew Wicklund To Discuss LGMD2I/R9 And BBP-418 Phase 3 Program Progress

<ul>
<li>U.S. commercial rollout of novel diagnostic platform to begin second half 2025</li>
<li>Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion</li>
</ul>

PSTV

Plus Therapeutics Provides A Business Update For Its Wholly-owned Subsidiary, CNSide Diagnostics, The CNSide Cerebrospinal Fluid Assay Platform Is Designed And Intended For Patients Suspected Of Having Central Nervous System Cancer Metastases

As blockchain technology adoption accelerates and digital assets become part of mainstream portfolios, one question looms large: How do we make these innovations work for everyone—not just early adopters and tech insiders?
Pamella Onoriode, a leading voice in financial inclusion and digital innovation, has made it her mission to answer that question. With a career spanning blockchain education, decentralized finance, and financial literacy for underrepresented communities, she brings both technical fluency and human focus to the conversation.
In this exclusive interview with The Champions Speakers Agency, Onoriode explores the real-world impact of blockchain beyond Bitcoin (BTC), offers practical frameworks for navigating crypto risk, and challenges traditional investing strategies with a bold, cycle-informed approach to long-term financial health.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="680" height="373" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25162334/Pamella-Onoriode.jpg" alt="" class="wp-image-14896" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25162334/Pamella-Onoriode.jpg 680w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25162334/Pamella-Onoriode-300x165.jpg 300w" sizes="(max-width: 680px) 100vw, 680px" /></figure>
<h3 class="wp-block-heading">Q: Beyond Bitcoin, how is blockchain technology being applied to real-world problems?</h3>
Pamella Onoriode: So, blockchain is so much more than Bitcoin. Yes, Bitcoin is the super queen of cryptocurrencies, but here are some amazing use cases:
<ul class="wp-block-list">
<li>Supply chain tracking – making sure that products we buy, for example, from food to fashion, are actually ethically sourced.</li>
<li>Smart contracts – automating agreements, reducing legal costs.</li>
<li>Financial inclusion – again, one of my favorites, is just giving unbanked communities access to money and financial services.</li>
</ul>
And I love blockchain technology because it&#8217;s decentralized power. There&#8217;s no middle human, and it&#8217;s just transparent.
<h3 class="wp-block-heading">Q: What are the key risks and rewards of investing in cryptocurrency today?</h3>
Pamella Onoriode: Yeah, so the benefits are:
<ul class="wp-block-list">
<li>Financial independence – you control your assets.</li>
<li>High growth potential – early adoption can lead to really big returns.</li>
<li>Global accessibility – so there&#8217;s no need for banks.</li>
</ul>
There are challenges, of course:
<ul class="wp-block-list">
<li>It&#8217;s volatile – the market moves really fast.</li>
<li>Security risks – scams and hacks are real.</li>
<li>Regulation uncertainty – you know, governments are still catching up.</li>
</ul>
And I, you know, I tell women: crypto isn&#8217;t just for tech bros. Financial literacy is power, and we should be part of that conversation.
<h3 class="wp-block-heading">Q: From your perspective, what strategies support long-term financial resilience through digital assets?</h3>
Pamella Onoriode: Okay, bear with me, but this is going to sound radical. I bet you&#8217;ve never heard this, right?
<ul class="wp-block-list">
<li>Invest according to your cycle – I make my best decisions in the follicular phase when my brain is at its sharpest. I know that I&#8217;ve been tracking for 15-odd years.</li>
<li>Diversify your portfolio – you&#8217;ve heard this one: don&#8217;t put everything into one coin.</li>
<li>Have a long-term mindset – ignore the hype and focus on fundamentals.</li>
</ul>
You know, I have great pleasure in educating my kids on financial freedom. My sons are little, but I already talk to them about the value of money and assets and long-term thinking. And I want them to grow up knowing that wealth isn&#8217;t just about money – it&#8217;s actually about choices.
This exclusive interview with <a href="https://champions-speakers.co.uk/speaker-agent/pamella-onoriode" target="_blank" rel="noreferrer noopener">Pamella Onoriode</a> was conducted by <a href="https://motivationalspeakersagency.co.uk/author/mark-matthews" target="_blank" rel="noreferrer noopener">Mark Matthews</a> of The Motivational Speakers Agency.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Opinion

Interview

'Crypto Isn't Just For Tech Bros': Pamella Onoriode On Blockchain Technology's Real-World Utility Beyond Bitcoin

DGNX

Diginex Joins S&P Global BMI Index, Signaling Credibility And Enhanced Market Visibility For Institutional Investors

Company recently reported strong Fiscal 2025 earnings growth and Fiscal 2026 growth outlook
Wiley(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>), a leading provider of authoritative content, data-driven insights, and knowledge services for the advancement of science, innovation and learning, today announced that its Board of Directors has declared a quarterly cash dividend of $0.355 per share on its Class A and Class B Common Stock, payable on July 24, 2025, to shareholders of record on July 8, 2025. The quarterly dividend is equivalent to an annual dividend of $1.42 per share, an increase from $1.41 per share in Fiscal 2025. It is Wiley's 32nd consecutive annual increase.
The Company also announced that its Board of Directors has approved a $250 million share repurchase authorization, an increase from the 2020 authorization of $200 million. In Fiscal 2025, Wiley allocated $76 million and $60 million to dividends and share repurchases, respectively.

Dividends

Buybacks

Wiley Board Approves $250M Share Repurchase Authorization, Increase From 2020 Authorization Of $200M; Raises Annual Dividend From $1.41 To $1.42 Per Share

Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.05) by 80 percent. This is a 280 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $20.869 million which missed the analyst consensus estimate of $21.181 million by 1.47 percent. This is a 20.98 percent decrease over sales of $26.411 million the same period last year.

Earnings

Earnings Misses

OESX

Orion Energy Sys Q4 EPS $(0.09) Misses $(0.05) Estimate, Sales $20.869M Miss $21.181M Estimate

ProPhase Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar days (the "Extension Notice") from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq (the "Bid Price Requirement"), following the expiration of the initial 180 calendar days period to regain compliance on June 24, 2025. NASDAQ stated that it based its determination to grant the extension based on the Company meeting all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement.
As previously announced, the Company received a written notification from Nasdaq dated December 26 2024, indicating that because the closing bid price of the Company's common shares for the previous 30 consecutive business days was below $1.00 per share, the Company was not in compliance with the Bid Price Requirement, and Nasdaq granted the Company a period of 180 calendar days, or until June 24, 2025, to regain compliance with the Bid Price Requirement.
As of the date hereof, the Company has not regained compliance with the Bid Price Requirement. Pursuant to the Extension Notice, the Company is eligible for an additional 180 calendar day period, or until December 22, 2025, to regain compliance with the Bid Price Requirement. To regain compliance, the Company's Class A ordinary shares must have a closing bid price of at least US$1.00 per share for a minimum of 10 consecutive business days. In the event that compliance cannot be demonstrated by December 22, 2025, the staff of Nasdaq will provide written notification that the Company's securities will be delisted.
The Company intends to monitor the closing bid price of its common shares between now and December 22, 2025, and is considering its options to regain compliance with the Bid Price Requirement. The Company believes that the Extension Notice does not affect the Company's business operations, its U.S. Securities and Exchange Commission reporting requirements, or its contractual obligations.

Government

Regulations

PRPH

ProPhase Labs Receives Nasdaq Extension Until December 2025 to Regain Compliance With $1.00 Bid Price Requirement

JP Morgan analyst Bill Peterson initiates coverage on Centrus Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LEU#AMEX">LEU</a>) with a Neutral rating and announces Price Target of $148.

JP Morgan Initiates Coverage On Centrus Energy with Neutral Rating, Announces Price Target of $148

Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#CSE">QNTM</a>) (FRA: 0K91) ("Quantum BioPharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd&#x2122;—the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms—is pleased to announce that it has engaged MZ Digital, a global leader in online marketing, and Dealmaker, a leading online platform for raising capital, to raise up to US$5 million through a Regulation D 506(c) offering. This format of raising capital allows businesses to sell and issue securities to accredited investors without a cap on the amount raised.

CSE:QNTM

QNTM

Quantum BioPharma Partners with Unbuzzd to Raise Up to $5M for Alcohol Metabolism Beverage

HC Wainwright &amp; Co. analyst Brandon Folkes initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPRX#NASDAQ">EPRX</a>) with a Buy rating and announces Price Target of $12.

EPRX

HC Wainwright & Co. Initiates Coverage On Eupraxia Pharmaceuticals with Buy Rating, Announces Price Target of $12

Acuity Inc. (NYSE: AYI) reported <a href="https://www.benzinga.com/pressreleases/25/06/g46110763/acuity-reports-fiscal-2025-third-quarter-results" target="_blank" rel="noreferrer noopener">fiscal third-quarter 2025</a> results on Thursday. The company reported quarterly net sales growth of 21.7% year-over-year to $1.18 billion, topping the analyst consensus estimate of $1.15 billion. 
It clocked an adjusted EPS of $5.12, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of $4.43.
Breaking down Acuity&#8217;s sales by segment shows strong growth in Acuity Intelligent Spaces (AIS), which surged to $264.1 million, a remarkable 248.9% increase from the previous year. Meanwhile, Acuity Brands Lighting (ABL) contributed $923.2 million, marking a 2.7% year-over-year rise.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44626729/acuity-brands-q2-earnings-tops-eps-estimates-intelligent-spaces-sales-surge-over-150-grows-margins-and-ebitda-despite-cash-flow-decline-and-sales-miss" rel="noreferrer noopener">Acuity Brands Q2 Earnings: Tops EPS Estimates, Intelligent Spaces Sales Surge Over 150%, Grows Margins, EBITDA Despite Cash Flow Decline And Sales Miss</a>
Operating margin declined by 310 bps to 11.9%, while profit declined by 3.8%. During the quarter, the company accelerated productivity actions in its ABL segment, which resulted in $29.7 million of special charges.&nbsp;
The consolidated adjusted operating margin grew by 150 bps to 18.8%. ABL&#8217;s adjusted operating margin improved by 80 bps to 18.8%. AIS&#8217; margin increased by 70 bps to 23.6%.
The company generated $207.3 million in operating cash flow for the first six months of fiscal year 2025, compared to $152.5 million a year ago. Free cash flow was $192.3 million.
Acuity held cash and equivalents of $371.8 million as of May 31, 2025, compared to $845.8 million as of August 31, 2024.
Adjusted EBITDA was $236.3 million, up from $180.0 million a year ago.&nbsp;The margin expanded by 140 bps to 20.0%.
Price Action: AYI saw its stock climb 1.35% to $291.38 in after-hours trading on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46100456/tesla-robotaxi-scaling-growth-will-be-slow-in-near-term-goldman-sachs" target="_blank" rel="noreferrer noopener">Tesla Robotaxi Scaling Growth Will Be Slow In Near Term: Goldman Sachs</a></li>
</ul>
Photo via Shutterstock

Comments

XCF Global Capital

Notizie

Ultime notizie per XCF Global Capital (NASDAQ:SAFX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO